Status:
COMPLETED
Analysis of Diphenylcyclopropenone (DPCP) in Normals
Lead Sponsor:
Rockefeller University
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-60 years
Brief Summary
The drug diphenylcyclopropenone, or DPCP, modifies the immune system and has been shown to be effective in treating certain kinds of cancer. This study hopes to improve our understanding of how this d...
Detailed Description
The immune system is the primary line of defense against infections and other things perceived as foreign to the body. Unfortunately, this immune system often fails to eliminate tumors or other cancer...
Eligibility Criteria
Inclusion
- Male or non-pregnant female between 18 and 60 years of age
- Able to give verbal and written informed consent
- For women of childbearing potential (WOCBP) or in men whose partners may become pregnant, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study (while receiving study medication and for one month following the last dose of study medication). Acceptable forms of contraception are listed in the protocol.
- Must have a negative urine pregnancy test (for WOCBP)
Exclusion
- Subjects taking any of the following systemic or topical therapies within 4 weeks of enrollment: corticosteroids, immunosuppressants, and/or any other medications that may affect the outcome of the study
- Known sensitivity to bandage or adhesive tape.
- Subjects who have active localized or systemic medical conditions that, in the opinion of the investigator, would preclude or make unsafe their participation in the study
- Subjects with any underlying concomitant diagnosis that may influence immune reactions (e.g. eczema, psoriasis, lupus)
- Subjects who are nursing mothers, pregnant, or planning to become pregnant at anytime during the course of the study or within 30 days of study completion
- Subjects who are unable to comply with study procedures, communicate effectively, cooperate with the investigator, or are unable to understand the study
- Subjects who have been treated with another investigational device or drug within 30 days of enrollment
- HIV positive as determined by self-reported history and/or a HIV POCT at screening
- History, physical, social or lab findings suggestive of any medical or psychological condition that would, in the opinion of the PI, make the candidate ineligible for the study
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01452594
Start Date
October 1 2011
End Date
September 1 2013
Last Update
September 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Rockefeller University
New York, New York, United States, 10065